علاج سرطان القناة الصفراوية خارج الكبد غير القابل للاستئصال أو المنتشر مع التغييرات الجزيئية القابلة للاستهداف

References

Gemcitabine and cisplatin in combination with either durvalumab or pembrolizumab should be considered standard of care for the first-line systemic treatment of patients with unresectable or metastatic eCCA (LoE 2, strong recommendation, consensus).

Patients with unresectable or metastatic eCCA should receive molecular profiling to identify and therapeutically address actionable alterations and to support inclusion into clinical trials (LoE 2, strong recommendation, strong consensus).

DOI: 10.1016/j.jhep.2025.03.007